Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics

Jonathan D. Greenzaid,Lina J. Chan,Brittany M. Chandani,Nicholas R. Kiritsis,Steven R. Feldman
DOI: https://doi.org/10.1080/13543784.2024.2326625
2024-03-08
Expert Opinion on Investigational Drugs
Abstract:Introduction Atopic dermatitis (AD) is a common inflammatory cutaneous disease that arises due to dysregulation of the Th2 immune response, impaired skin barrier integrity, and dysbiosis of the skin and gut microbiota. An abundance of Staphylococcus aureus biofilms in AD lesions increases the Th2 immune response, and gut bacteria release breakdown products such as Short Chain Fatty Acids that regulate the systemic immune response.
pharmacology & pharmacy
What problem does this paper attempt to address?